So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs

ABSTRACTBackground: PTSD is a significant mental health problem worldwide. Current evidence-based interventions suffer various limitations. Ketamine is a novel agent that is hoped to be incrementally better than extant interventions.Objective: Several randomized control trials (RCTs) of ketamine int...

Full description

Bibliographic Details
Main Authors: Nicholas C. Borgogna, Tyler Owen, Jacob Vaughn, David A. L. Johnson, Stephen L. Aita, Benjamin D. Hill
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:European Journal of Psychotraumatology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20008066.2023.2299124
_version_ 1797354934297952256
author Nicholas C. Borgogna
Tyler Owen
Jacob Vaughn
David A. L. Johnson
Stephen L. Aita
Benjamin D. Hill
author_facet Nicholas C. Borgogna
Tyler Owen
Jacob Vaughn
David A. L. Johnson
Stephen L. Aita
Benjamin D. Hill
author_sort Nicholas C. Borgogna
collection DOAJ
description ABSTRACTBackground: PTSD is a significant mental health problem worldwide. Current evidence-based interventions suffer various limitations. Ketamine is a novel agent that is hoped to be incrementally better than extant interventions.Objective: Several randomized control trials (RCTs) of ketamine interventions for PTSD have now been published. We sought to systematically review and meta-analyse results from these trials to evaluate preliminary evidence for ketamine’s incremental benefit above-and-beyond control interventions in PTSD treatment.Results: Omnibus findings from 52 effect sizes extracted across six studies (n = 221) yielded a small advantage for ketamine over control conditions at reducing PTSD symptoms (g = 0.27, 95% CI = 0.03, 0.51). However, bias-correction estimates attenuated this effect (adjusted g = 0.20, 95%, CI = −0.08, 0.48). Bias estimates indicated smaller studies reported larger effect sizes favouring ketamine. The only consistent timepoint assessed across RCTs was 24-hours post-initial infusion. Effects at 24-hours post-initial infusion suggest ketamine has a small relative advantage over controls (g = 0.35, 95% CI = 0.06, 0.64). Post-hoc analyses at 24-hours post-initial infusion indicated that ketamine was significantly better than passive controls (g = 0.44, 95% CI = 0.03, 0.85), but not active controls (g = 0.24, 95% CI = −0.30, 0.78). Comparisons one-week into intervention suggested no meaningful group differences (g = 0.24, 95% CI = 0.00, 0.48). No significant differences were evident for RCTs that examined effects two-weeks post initial infusion (g = 0.17, 95% CI = −0.10, 0.44).Conclusions: Altogether, ketamine-for-PTSD RCTs reveal a nominal initial therapeutic advantage relative to controls. However, bias and heterogeneity appear problematic. While rapid acting effects were observed, all control agents (including saline) also evidenced rapid acting effects. We argue blind penetration to be a serious concern, and that placebo is the likely mechanism behind reported therapeutic effects.
first_indexed 2024-03-08T13:56:59Z
format Article
id doaj.art-4336dd68f518444dac827fe5faa791c8
institution Directory Open Access Journal
issn 2000-8066
language English
last_indexed 2024-03-08T13:56:59Z
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series European Journal of Psychotraumatology
spelling doaj.art-4336dd68f518444dac827fe5faa791c82024-01-15T11:32:26ZengTaylor & Francis GroupEuropean Journal of Psychotraumatology2000-80662024-12-0115110.1080/20008066.2023.2299124So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTsNicholas C. Borgogna0Tyler Owen1Jacob Vaughn2David A. L. Johnson3Stephen L. Aita4Benjamin D. Hill5Department of Psychological Sciences, Texas Tech University, Lubbock, TX, USADepartment of Psychological Sciences, Texas Tech University, Lubbock, TX, USADepartment of Psychological Sciences, Texas Tech University, Lubbock, TX, USADepartment of Psychological Sciences, Texas Tech University, Lubbock, TX, USAVeterans Affairs Maine Healthcare System, Augusta, ME, USADepartment of Psychology, University of South Alabama, Mobile, AL, USAABSTRACTBackground: PTSD is a significant mental health problem worldwide. Current evidence-based interventions suffer various limitations. Ketamine is a novel agent that is hoped to be incrementally better than extant interventions.Objective: Several randomized control trials (RCTs) of ketamine interventions for PTSD have now been published. We sought to systematically review and meta-analyse results from these trials to evaluate preliminary evidence for ketamine’s incremental benefit above-and-beyond control interventions in PTSD treatment.Results: Omnibus findings from 52 effect sizes extracted across six studies (n = 221) yielded a small advantage for ketamine over control conditions at reducing PTSD symptoms (g = 0.27, 95% CI = 0.03, 0.51). However, bias-correction estimates attenuated this effect (adjusted g = 0.20, 95%, CI = −0.08, 0.48). Bias estimates indicated smaller studies reported larger effect sizes favouring ketamine. The only consistent timepoint assessed across RCTs was 24-hours post-initial infusion. Effects at 24-hours post-initial infusion suggest ketamine has a small relative advantage over controls (g = 0.35, 95% CI = 0.06, 0.64). Post-hoc analyses at 24-hours post-initial infusion indicated that ketamine was significantly better than passive controls (g = 0.44, 95% CI = 0.03, 0.85), but not active controls (g = 0.24, 95% CI = −0.30, 0.78). Comparisons one-week into intervention suggested no meaningful group differences (g = 0.24, 95% CI = 0.00, 0.48). No significant differences were evident for RCTs that examined effects two-weeks post initial infusion (g = 0.17, 95% CI = −0.10, 0.44).Conclusions: Altogether, ketamine-for-PTSD RCTs reveal a nominal initial therapeutic advantage relative to controls. However, bias and heterogeneity appear problematic. While rapid acting effects were observed, all control agents (including saline) also evidenced rapid acting effects. We argue blind penetration to be a serious concern, and that placebo is the likely mechanism behind reported therapeutic effects.https://www.tandfonline.com/doi/10.1080/20008066.2023.2299124KetaminePTSDrandomized control trialsmeta-analysisbiasKetamina
spellingShingle Nicholas C. Borgogna
Tyler Owen
Jacob Vaughn
David A. L. Johnson
Stephen L. Aita
Benjamin D. Hill
So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
European Journal of Psychotraumatology
Ketamine
PTSD
randomized control trials
meta-analysis
bias
Ketamina
title So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
title_full So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
title_fullStr So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
title_full_unstemmed So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
title_short So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
title_sort so how special is special k a systematic review and meta analysis of ketamine for ptsd rcts
topic Ketamine
PTSD
randomized control trials
meta-analysis
bias
Ketamina
url https://www.tandfonline.com/doi/10.1080/20008066.2023.2299124
work_keys_str_mv AT nicholascborgogna sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts
AT tylerowen sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts
AT jacobvaughn sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts
AT davidaljohnson sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts
AT stephenlaita sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts
AT benjamindhill sohowspecialisspecialkasystematicreviewandmetaanalysisofketamineforptsdrcts